Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 121,900 shares, an increase of 26.3% from the February 28th total of 96,500 shares. Based on an average daily volume of 36,200 shares, the short-interest ratio is presently 3.4 days. Currently, 0.6% of the company’s stock are short sold.

Institutional Investors Weigh In On Rafael

An institutional investor recently raised its position in Rafael stock. Geode Capital Management LLC raised its holdings in Rafael Holdings, Inc. (NYSE:RFL) by 17.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,561 shares of the company’s stock after buying an additional 26,493 shares during the period. Geode Capital Management LLC owned about 0.71% of Rafael worth $288,000 as of its most recent SEC filing. 11.30% of the stock is currently owned by institutional investors and hedge funds.

Rafael Price Performance

Shares of NYSE RFL opened at $1.88 on Thursday. The company has a market cap of $46.84 million, a price-to-earnings ratio of -1.13 and a beta of 1.15. The stock’s 50-day moving average is $1.97 and its two-hundred day moving average is $1.92. Rafael has a 1-year low of $1.29 and a 1-year high of $2.50.

Rafael (NYSE:RFL) last released its earnings results on Thursday, March 13th. The company reported ($0.06) earnings per share for the quarter. Rafael had a negative return on equity of 53.71% and a negative net margin of 5,707.03%. The firm had revenue of $0.08 million for the quarter.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.